While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.
Sanofi’s global head of research and development, John Reed, has described biosimilars as an “enormous distraction” for a company pursuing novel therapies.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
